Clinical Trial Update: Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating dasatinib, cytarabine, and idarubicin in high-risk acute myeloid leukemia was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• DASATINIB (Dasatinib)
• Idarubicin (idarubicin)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-09-16